ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2013
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer.Journal for immunotherapy of cancer · 2025Review
- Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.Journal of the National Cancer Institute · 2020Review
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.Journal of the National Cancer Institute · 2017Review
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.Journal for immunotherapy of cancer · 2016Article
- Immunotherapy in prostate cancer: review of the current evidence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015Review
- Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.Therapeutic advances in vaccines · 2014Review
- Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Cancer vaccines.Hematology/oncology clinics of North America · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Results of recent clinical trials have intensified interest in immunotherapy for cancer. Among the most promising candidates for immunotherapy are patients with prostate cancer. Results of therapeutic vaccine clinical trials in this population have suggested statistically significant and clinically meaningful improvements in overall survival, with substantially fewer side effects than with chemotherapy. Of particular interest are sipuleucel-T, the first U.S. Food and Drug Administration-approved therapeutic cancer vaccine, and PSA-TRICOM (PROSTVAC), a therapeutic cancer vaccine in phase III testing. The immune checkpoint inhibitor ipilimumab is also stirring considerable interest, with two phase III trials ongoing in prostate cancer. This article highlights data emerging from these trials and addresses remaining questions and practical clinical implications of this therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.